Skip to main content
NCBI home page
Emerging Infectious Diseases logoLink to Emerging Infectious Diseases
letter
. 2008 May;14(5):863. doi: 10.3201/eid1405.071440

Rotavirus P[4]G2 in a Vaccinated Population, Brazil

Manish M Patel *,✉, Lucia Helena de Oliveira †, Ana Maria Bispo †, Jon Gentsch *, Umesh D Parashar *
PMCID: PMC2600230  PMID: 18439390

To the Editor

Gurgel et al. provide an early examination of postmarketing surveillance data from Brazil, one of the first countries to implement routine childhood immunization with Rotarix vaccine. In a community with reported vaccination coverage of 50%, the P[4]G2 strain was detected in all 21 rotavirus-positive stool samples identified during November 2006–February 2007. Although monitoring effectiveness of Rotarix against P[4]G2 strains is of interest, the small sample size, short duration of surveillance, and lack of a comparison group preclude firm assessment of an association between P[4]G2 predominance and vaccination.

Because Rotarix was introduced in Brazil in March 2006, most children >12 months old (66 [51%] of 129) in the study were ineligible for vaccination. Genotype P[4]G2 was the only strain identified even in older children, which suggests either a change in disease ecology from vaccination or the random circulation of P[4]G2 strains in the community. Ongoing hospital-based surveillance during 2006 in 3 regional countries that had not introduced rotavirus vaccine (El Salvador, Guatemala, and Honduras) showed that P[4]G2 was the predominant circulating strain (prevalence 68%–81%). Thus, as previously documented, the predominance of P[4]G2 strains after Rotarix introduction in Brazil could represent a natural shift unrelated to vaccination.

Evaluation of vaccine effectiveness against specific strains will allow full assessment of the public health impact of vaccination. Although the data are sparse in the study from Gurgel et al., a comparison of the odds of vaccination among rotavirus-positive (cases) versus rotavirus-negative (controls) children shows 80% vaccine effectiveness against P[4]G2 strains among infants <1 year of age, in accordance with recently published data from a controlled trial. To further elucidate vaccine impact, we are providing support for vaccine effectiveness studies in Nicaragua and El Salvador and conducting strain monitoring before and after licensure throughout Latin America.

Footnotes

Suggested citation for this article: Patel MM, de Oliveira LH, Bispo AM, Gentsch J, Parashar UD. Rotavirus P[4]G2 in a vaccinated population, Brazil [letter]. Emerg Infect Dis [serial on the Internet]. 2008 May [date cited]. Available from http://www.cdc.gov/EID/content/14/5/863.htm

References

  • 1.Gurgel RQBB, Cuevas LE, Vieira SCF, Barros VCF, Fontes PB, Salustino ET, et al. Predominance of rotavirus P[4]G2 in a vaccinated population, Brazil. Emerg Infect Dis. 2007;13:1571–3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Glass RI, Parashar UD, Bresee JS, Turcios R, Fischer TK, Widdowson MA, et al. Rotavirus vaccines: current prospects and future challenges. Lancet. 2006;368:323–32. 10.1016/S0140-6736(06)68815-6 [DOI] [PubMed] [Google Scholar]
  • 3.Desselberger U, Iturriza-Gomara M, Gray JJ. Rotavirus epidemiology and surveillance. Novartis Found Symp. 2001;238:125–47. [DOI] [PubMed] [Google Scholar]
  • 4.Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol. 2005;15:29–56. 10.1002/rmv.448 [DOI] [PubMed] [Google Scholar]
  • 5.Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet. 2007;370:1757–63. 10.1016/S0140-6736(07)61744-9 [DOI] [PubMed] [Google Scholar]
Emerg Infect Dis. 2008 May;14(5):863.

In Response

Ricardo Queiroz Gurgel *,†,✉, Sarah Cristina Fontes Vieira *, Vanessa Cristiane Farias Barros *, Paula Brandão Fontes *, Eduardo F Salustino *, Osamu Nakagomi ‡, Toyoko Nakagomi ‡, Winifred Dove †, Nigel A Cunliffe †, Luis E Cuevas †,§

We acknowledge the comments by Patel et al. (1) and by Linhares and Velázquez (2) about our article that documented the presence of a single rotavirus genotype (P[4]G2) in Aracaju, northeastern Brazil, after the introduction of a human, monovalent rotavirus vaccine (3). Both letters emphasize that the predominance of P[4]G2 may be caused by a natural genotype variation unrelated to vaccination. We agree that our observation could be explained by natural variation of circulating rotavirus genotypes in the region, but an alternative possibility is that the introduction of the G1P[8] rotavirus vaccine into the childhood immunization schedule created conditions in which P[4]G2 strains had a selective advantage over strains with which the vaccine shares G type, P type, or both.

According to a systematic review of rotavirus genotypes reported in the 25 years preceding introduction of the vaccine in Brazil, the prevalence of P[4]G2 strains varied from 19% (1986–1995) to 12% (1996–2000) to 1% thereafter, thus not reaching the detection rate we observed in Aracaju (R.Q. Gurgel et al., unpub data). Furthermore, in the ensuing 8-month period, no genotype other than P[4]G2 had been detected in Aracaju, suggesting that our initial findings were not spurious (R.Q. Gurgel et al., unpub data). In addition, in a separate study we conducted in Recife, a city 500 km north of Aracaju, we observed a significant increase in the proportion of G2 strains detected from 47% (21/45) during the 3-month period immediately after vaccine introduction (March 2006–May 2006) to 100% (11/11) during the same 3-month period 1 year after the vaccine introduction (March 2007–May 2007) (4). We believe that our findings are consistent with results of field trials that indicated that the vaccine provided relatively less protection against P[4]G2 strains than against other rotavirus strain types (5).

The beneficial impact of rotavirus vaccination in northeastern Brazil is reflected in the reduction of the detection rate of rotavirus among severe diarrhea cases in our study in Recife, which fell from 27% (45/166 cases) to 5.0% (11/221 cases) in the postvaccine 3-month reporting periods, respectively (4). Our data from Aracaju are indicative of heterotypic protection, although this is not statistically significant (1), against P[4]G2 strains. Further postlicensure studies in Brazil are required to document continuing effectiveness of the national vaccination program as well as to closely monitor the circulating rotavirus strain types (6).

References

  • 1.Patel MM, de Oliveira LH, Bispo AM, Gentsch J, Parashar UD. Rotavirus P[4]G2 in a vaccinated population, Brazil [letter]. Emerg Infect Dis. 2008;14:863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Linhares AC, Velázquez FR. Rotavirus P[4]G2 in a vaccinated population, Brazil [letter]. Emerg Infect Dis. 2008;14:864. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Gurgel RQ, Cuevas LE, Vieira SCF, Barros VCF, Fontes PB, Salustino ET, et al. Predominance of rotavirus P[4]G2 in a vaccinated population, Brazil. Emerg Infect Dis. 2007;13:1571–3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Nakagomi T, Cuevas LE, Gurgel RQ, Elrokhsi SH, Belkhir YA, Abugalia M, et al. Apparent extinction of non-G2 rotavirus strains from circulation in Recife, Brazil, after the introduction of rotavirus vaccine. [PMID: 18175037]. Arch Virol. 2008;153:591–3. 10.1007/s00705-007-0028-z [DOI] [PubMed] [Google Scholar]
  • 5.Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354:11–22. 10.1056/NEJMoa052434 [DOI] [PubMed] [Google Scholar]
  • 6.Rotavirus vaccines. Wkly Epidemiol Rec. 2007;82:285–96. [PubMed] [Google Scholar]

Articles from Emerging Infectious Diseases are provided here courtesy of Centers for Disease Control and Prevention

RESOURCES